Hemoglobin
A1c (glycated hemoglobin) reflects the average blood glucose concentration over
the course of the RBC lifespan, roughly 120 days in normal individuals. As the
average plasma glucose increases, so does the amount of glycated hemoglobin in
the plasma. Limitation of hemoglobin A1c is that it does not provide any
indication of the changes in glucose concentrations throughout the day, for
which frequent glucose measurements are needed.
The
equation to calculate eAG (in mg/dL) from hemoglobin A1c (in %) is as follows:
eAG
(mg/dL) = 28.7 x NGSP-A1c (%) – 46.7
The
Diabetes Control and Complications Trial (DCCT) reported that a higher mean A1c
level was the dominant predictor of diabetic retinopathy progression. Tighter
control shown by levels of HbA1c in the 7% range or lower, were correlated with
35-76% decrease in microvascular complications, like retinopathy, nephropathy
and neuropathy, in patients with type 1 diabetes. The
extension of DCCT into EDIC study showed benefit in the cardiovascular risk and
mortality in the long-term for those patients with lower levels of HbA1c.
A1c
exhibited direct correlations with cholesterol, triglycerides, and LDL and
inverse correlation with HDL cholesterol. A1c
is identified as a significant risk factor for cardiovascular diseases and
stroke in subjects who may have diabetes.
Women
with HbA1c 5.7%–6.4% have a significantly higher risk of progression to GDM
compared with women with normal HgbA1c values and should be considered for
closer GDM surveillance and possible intervention.
ADA
Recommendations:
Older
adults who are otherwise healthy with few coexisting chronic illnesses and
intact cognitive function and functional status should have lower glycemic
goals (such as A1C <7.0–7.5%), while those with multiple coexisting chronic
illnesses, cognitive impairment, or functional dependence should have less
stringent glycemic goals (such as A1C <8.0–8.5%).
Since
the lifespan of RBCs is about 120 days, glycated hemoglobin (hemoglobin A1c)
represents a measurement of the average blood glucose level over the past 2 to
3 months. Serum proteins are present in the blood for a shorter time, about 14
to 21 days, so glycated proteins, and the fructosamine test, reflect average
glucose levels over 2 to 3 weeks.
Instances
where fructosamine may be considered over A1c include:
- Rapid
changes in diabetes treatment
- Diabetic
pregnancy
- Shortened
RBC life span, such as hemolytic anemia or blood loss. When the lifespan of
RBCs in circulation is shortened, the A1c result is falsely low and is an
unreliable measurement of a person's average glucose over time.
- Abnormal
forms of hemoglobin – the presence of some hemoglobin variants, such as
hemoglobin S in sickle cell anemia, may affect certain methods for measuring
A1c.
National
Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) recommends
against the use of the A1c test in patients with the hemoglobin variants HbSS,
HbSC, or HbCC as these patients may suffer from conditions that affect the A1c
test, such as anemia, increased RBC turn-over, and frequent blood transfusions.